Graphy targets North American market with SMA 3D-printed clear aligner at AAO 2026

Graphy, led by CEO Shim Woon-seop, successfully exhibited its shape-memory alloy (SMA) 3D-printed clear aligner system at the American Association of Orthodontists (AAO) 2026 meeting, held in May 2026. The company reported several concrete outcomes from the event: direct on-site sales roughly covering the cost of participation, engagement with approximately 40 North American dental schools including Harvard, UCLA, and the University of Pennsylvania for system adoption and joint research, and a formalized entry into Canada with a launch show scheduled for June 28, 2026, targeting over 200 local orthodontists. Graphy also announced partnerships with Dental Monitoring for AI-based remote treatment tracking and ClearForward, which will establish a dedicated SMA design team to ease clinician workflow integration. Additionally, Graphy is exploring sequential collaboration with Heartland Dental and other top-tier North American DSOs representing over 450 orthodontic specialty clinics.

This move places Graphy in direct competition with Align Technology, the dominant player in the clear aligner market and the largest production user of vat photopolymerization (VPP) globally. Graphy’s differentiation lies in its SMA material, which uses a 3D-printed shape-memory polymer that applies continuous, low-force tooth movement, potentially reducing treatment time and improving patient comfort compared to traditional thermoformed aligners. The company is effectively targeting the medical-dental vertical, specifically the orthodontic segment, where Align’s iTero scanner and Invisalign system have created a deeply embedded workflow and brand lock-in. Graphy’s strategy mirrors the classic Chinese localization arc (Pattern P2) but from a Korean base: a regional entrant leveraging a novel material science advantage to challenge an incumbent’s supply chain and clinical reference dominance. The engagement with 40 dental schools suggests Graphy is investing in the aerospace qualification grind equivalent for medical devices — embedding its technology in academic curricula and clinical research to build the switching costs and evidence base needed for long-term adoption.

For Graphy, the near-term execution challenge is clear: converting academic interest and DSO exploratory talks into signed contracts and recurring case volume. The company must demonstrate that its SMA system can match or exceed Align’s clinical outcomes across a broad patient population, not just in pilot studies. The Canadian launch show in June will be an early test of commercial traction outside Korea. Buyers — orthodontists and DSOs — should evaluate Graphy’s claims against published clinical data and workflow integration costs, particularly the time required to train staff on a new digital design and monitoring pipeline. The partnerships with Dental Monitoring and ClearForward are sensible steps to reduce friction, but the ultimate proof will be in patient outcomes and practice profitability, not booth traffic at AAO.